Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial

J. Bitran, A. Billings, R. K. Desser, L. Cohen, M. Colman, C. Shapiro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In 25 patients with lung cancer, treated with actinomycin D and vincristine (V D) with only one objective response (IMD), the survival was compared retrospectively to a group of 49 consecutive patients treated with radiotherapy only during the same time period. Median survival times for the V D group and radiotherapy controls were 6.5 and 7.5 mth, respectively. It is concluded that V D did not increase survival in patients with lung cancer and should be dropped from the chemotherapeutic armamentarium in lung cancer.

Original languageEnglish (US)
Pages (from-to)1669-1672
Number of pages4
JournalCancer
Volume37
Issue number4
DOIs
StatePublished - 1976
Externally publishedYes

Fingerprint

Dactinomycin
Vincristine
Lung Neoplasms
Survival
Radiotherapy
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial. / Bitran, J.; Billings, A.; Desser, R. K.; Cohen, L.; Colman, M.; Shapiro, C.

In: Cancer, Vol. 37, No. 4, 1976, p. 1669-1672.

Research output: Contribution to journalArticle

Bitran, J. ; Billings, A. ; Desser, R. K. ; Cohen, L. ; Colman, M. ; Shapiro, C. / Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial. In: Cancer. 1976 ; Vol. 37, No. 4. pp. 1669-1672.
@article{daffa8166143469b88cb45e7e0a4c386,
title = "Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial",
abstract = "In 25 patients with lung cancer, treated with actinomycin D and vincristine (V D) with only one objective response (IMD), the survival was compared retrospectively to a group of 49 consecutive patients treated with radiotherapy only during the same time period. Median survival times for the V D group and radiotherapy controls were 6.5 and 7.5 mth, respectively. It is concluded that V D did not increase survival in patients with lung cancer and should be dropped from the chemotherapeutic armamentarium in lung cancer.",
author = "J. Bitran and A. Billings and Desser, {R. K.} and L. Cohen and M. Colman and C. Shapiro",
year = "1976",
doi = "10.1002/1097-0142(197604)37:4<1669::AID-CNCR2820370409>3.0.CO;2-N",
language = "English (US)",
volume = "37",
pages = "1669--1672",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial

AU - Bitran, J.

AU - Billings, A.

AU - Desser, R. K.

AU - Cohen, L.

AU - Colman, M.

AU - Shapiro, C.

PY - 1976

Y1 - 1976

N2 - In 25 patients with lung cancer, treated with actinomycin D and vincristine (V D) with only one objective response (IMD), the survival was compared retrospectively to a group of 49 consecutive patients treated with radiotherapy only during the same time period. Median survival times for the V D group and radiotherapy controls were 6.5 and 7.5 mth, respectively. It is concluded that V D did not increase survival in patients with lung cancer and should be dropped from the chemotherapeutic armamentarium in lung cancer.

AB - In 25 patients with lung cancer, treated with actinomycin D and vincristine (V D) with only one objective response (IMD), the survival was compared retrospectively to a group of 49 consecutive patients treated with radiotherapy only during the same time period. Median survival times for the V D group and radiotherapy controls were 6.5 and 7.5 mth, respectively. It is concluded that V D did not increase survival in patients with lung cancer and should be dropped from the chemotherapeutic armamentarium in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0017134257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017134257&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197604)37:4<1669::AID-CNCR2820370409>3.0.CO;2-N

DO - 10.1002/1097-0142(197604)37:4<1669::AID-CNCR2820370409>3.0.CO;2-N

M3 - Article

VL - 37

SP - 1669

EP - 1672

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -